Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio’s DNA and RNA business.

With the modality now in early clinical trials, experts say more efficiency, broader editing capabilities and delivery breakthroughs are needed to propel RNA editing to the next stage.

A new discovery offers hope for Huntington’s disease. This discovery provides hope that a DNA repair process may help slow or stop disease progression.

There are many molecules with therapeutic potential, but it can be a challenge to deliver them to the right places at the right times.. | Cell And Molecular Biology

This week at AAAS, PNNL scientists and colleagues discuss phenomics, exposomics, and the factors that influence DNA instructions to bring about the world around us.

At the cellular level, pieces of important genetic information, called small RNA, have the ability to introduce important so-called epigenetic changes. These alterations allow an individual to survive a potential threat, such as a disease or a toxin in the environment, without altering their DNA.

California-based nonprofit Arc Institute and Stanford University, in collaboration with NVIDIA, unveiled Evo 2 on Wednesday as the largest publicly available AI model for genomic data. Evo 2 can predict and design the genetic code—DNA,

To learn about the progress being made in the RNA therapeutics space, we spoke to CTO and Co-Founder of La Jolla Labs, Jeff Milton, at the 2025 SLAS international meeting in San Diego.

Spliceosomes help cells remove large chunks of non-coding genetic information—called introns—from the precursors of messenger RNA (pre-mRNA), the molecule responsible for transferring genetic information from DNA into proteins. Spliceosomes act as an ...

RNA splicing is a cellular process that is critical for gene expression. After genes are copied from DNA into messenger RNA, portions of the RNA that don't code for proteins, called introns, are cut out and the coding portions are spliced back together.

RNA-based therapeutics have rapidly emerged over the past decade, offering a new class of medicines that differ significantly from conventional drugs. These therapies can be programmed to target or restore defective genes,

Maravai LifeSciences Inc., a provider of life science reagents and services to researchers and biotech innovators, has completed its previously announced acqu i sition of Officinae Bio’s DNA and RNA business.